Two for one

Viral helicases as an ideal target for HIV and HCV co-infection

Muhammad Faraz Anwar, Shamshad Zarina, Syed Ali, Syed Hani Abidi

Research output: Contribution to journalLetter

Abstract

Helicase enzyme is responsible for the unwinding of complementary nucleic acid strands, which is one of the preliminary steps in DNA replication. They are crucial for replication of an organism, including viruses. HCV and HIV are two clinically significant pathogens, responsible for millions of infections and deaths worldwide. Due to similar transmission routes, these viruses can establish co-infection in an individual. Individually, these infections are difficult to treat, however, in case of co-infection, the treatment becomes more difficult. Additionally, these viruses accumulate mutation in response to drug therapy that renders the treatment ineffective. HCV and HIV both encode enzyme containing helicase activity. The viral-encoded helicase plays a significant role in HIV and HCV life cycle. Here we propose viral helicases as an ideal single-hit target that can inhibit HIV and HCV co-infection. We also hypothesize that search for natural analogs sharing basic ring structure with a class of helicase inhibitors called fluoroquinolones can yield natural agents with superior antiviral (anti-helicase) activity with lower toxicity index. The fluoroquinolones and their analogs are currently not part of any antiviral regimens. Our proposal is to include fluoroquinolones-derived natural analogs as a conjugate therapy along with main regimens available against HCV and HIV co-infection.

Original languageEnglish
Pages (from-to)139-140
Number of pages2
JournalMedical Hypotheses
Volume116
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Coinfection
Fluoroquinolones
HIV
Viruses
Antiviral Agents
Enzymes
Infection
Life Cycle Stages
DNA Replication
Nucleic Acids
HIV Infections
Therapeutics
Drug Therapy
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Two for one : Viral helicases as an ideal target for HIV and HCV co-infection. / Anwar, Muhammad Faraz; Zarina, Shamshad; Ali, Syed; Abidi, Syed Hani.

In: Medical Hypotheses, Vol. 116, 01.07.2018, p. 139-140.

Research output: Contribution to journalLetter

Anwar, Muhammad Faraz ; Zarina, Shamshad ; Ali, Syed ; Abidi, Syed Hani. / Two for one : Viral helicases as an ideal target for HIV and HCV co-infection. In: Medical Hypotheses. 2018 ; Vol. 116. pp. 139-140.
@article{8944ed668b9e41f1871b54bcd49d84f7,
title = "Two for one: Viral helicases as an ideal target for HIV and HCV co-infection",
abstract = "Helicase enzyme is responsible for the unwinding of complementary nucleic acid strands, which is one of the preliminary steps in DNA replication. They are crucial for replication of an organism, including viruses. HCV and HIV are two clinically significant pathogens, responsible for millions of infections and deaths worldwide. Due to similar transmission routes, these viruses can establish co-infection in an individual. Individually, these infections are difficult to treat, however, in case of co-infection, the treatment becomes more difficult. Additionally, these viruses accumulate mutation in response to drug therapy that renders the treatment ineffective. HCV and HIV both encode enzyme containing helicase activity. The viral-encoded helicase plays a significant role in HIV and HCV life cycle. Here we propose viral helicases as an ideal single-hit target that can inhibit HIV and HCV co-infection. We also hypothesize that search for natural analogs sharing basic ring structure with a class of helicase inhibitors called fluoroquinolones can yield natural agents with superior antiviral (anti-helicase) activity with lower toxicity index. The fluoroquinolones and their analogs are currently not part of any antiviral regimens. Our proposal is to include fluoroquinolones-derived natural analogs as a conjugate therapy along with main regimens available against HCV and HIV co-infection.",
author = "Anwar, {Muhammad Faraz} and Shamshad Zarina and Syed Ali and Abidi, {Syed Hani}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.mehy.2018.05.004",
language = "English",
volume = "116",
pages = "139--140",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Two for one

T2 - Viral helicases as an ideal target for HIV and HCV co-infection

AU - Anwar, Muhammad Faraz

AU - Zarina, Shamshad

AU - Ali, Syed

AU - Abidi, Syed Hani

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Helicase enzyme is responsible for the unwinding of complementary nucleic acid strands, which is one of the preliminary steps in DNA replication. They are crucial for replication of an organism, including viruses. HCV and HIV are two clinically significant pathogens, responsible for millions of infections and deaths worldwide. Due to similar transmission routes, these viruses can establish co-infection in an individual. Individually, these infections are difficult to treat, however, in case of co-infection, the treatment becomes more difficult. Additionally, these viruses accumulate mutation in response to drug therapy that renders the treatment ineffective. HCV and HIV both encode enzyme containing helicase activity. The viral-encoded helicase plays a significant role in HIV and HCV life cycle. Here we propose viral helicases as an ideal single-hit target that can inhibit HIV and HCV co-infection. We also hypothesize that search for natural analogs sharing basic ring structure with a class of helicase inhibitors called fluoroquinolones can yield natural agents with superior antiviral (anti-helicase) activity with lower toxicity index. The fluoroquinolones and their analogs are currently not part of any antiviral regimens. Our proposal is to include fluoroquinolones-derived natural analogs as a conjugate therapy along with main regimens available against HCV and HIV co-infection.

AB - Helicase enzyme is responsible for the unwinding of complementary nucleic acid strands, which is one of the preliminary steps in DNA replication. They are crucial for replication of an organism, including viruses. HCV and HIV are two clinically significant pathogens, responsible for millions of infections and deaths worldwide. Due to similar transmission routes, these viruses can establish co-infection in an individual. Individually, these infections are difficult to treat, however, in case of co-infection, the treatment becomes more difficult. Additionally, these viruses accumulate mutation in response to drug therapy that renders the treatment ineffective. HCV and HIV both encode enzyme containing helicase activity. The viral-encoded helicase plays a significant role in HIV and HCV life cycle. Here we propose viral helicases as an ideal single-hit target that can inhibit HIV and HCV co-infection. We also hypothesize that search for natural analogs sharing basic ring structure with a class of helicase inhibitors called fluoroquinolones can yield natural agents with superior antiviral (anti-helicase) activity with lower toxicity index. The fluoroquinolones and their analogs are currently not part of any antiviral regimens. Our proposal is to include fluoroquinolones-derived natural analogs as a conjugate therapy along with main regimens available against HCV and HIV co-infection.

UR - http://www.scopus.com/inward/record.url?scp=85048719918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048719918&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2018.05.004

DO - 10.1016/j.mehy.2018.05.004

M3 - Letter

VL - 116

SP - 139

EP - 140

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

ER -